eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

In AMPLIFY, in patients receiving treatment for DVT and PE, ELIQUIS demonstrated comparable efficacy and a significant reduction in the risk of major bleeding compared with enoxaparin / warfarin.1*

Discover the data supporting ELIQUIS in DVT / PE

The full publication is available to read

Bar chart of primary efficacy and safety results of ELIQUIS vs. enoxaparin / warfarin from the AMPLIFY clinical trial

Adapted from Agnelli et al. 2013.1

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

* The AMPLIFY clinical trial was a randomised, double-blind, non-inferiority trial in 5,395 patients with acute VTE. Recurrent symptomatic VTE or VTE-related death was the primary efficacy endpoint whilst major bleeding was the primary safety outcome.1 Efficacy analyses were based on ITT population for whom the outcome status at 6 months was documented. Safety analyses were based on patients who had at least one dose of study drug.1
† The primary efficacy endpoint was the incidence of the adjudicated composite of recurrent symptomatic VTE or death related to VTE.1 Recurrent VTE included fatal or non-fatal PE and DVT.1 The primary safety endpoint was major bleeding.1
‡ This link is to a third-party site unaffiliated with the Pfizer / BMS Alliance. Please abide by the terms of use of the site.

AMPLIFY = Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy ARR = Absolute Risk Reduction CI = Confidence Interval DVT = Deep Vein Thrombosis ITT= Intention-to-Treat N = Total number of patients in the ELIQUIS group of the enoxaparin / warfarin group n = Number of patients with event PE = Pulmonary Embolism RR = Relative Risk RRR = Relative Risk Reduction VTE = Venous Thromboembolic Events


  1. Agnelli G et al. N Engl J Med 2013; 369: 799–808.